{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028563","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.344380+00:00","generated_at":"2026-06-11T21:31:33.468642+00:00","sec_items":["2.02","5.03","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cardiff Oncology shifts lead program to first-line RAS-mutated mCRC; Q2 cash burn $7.1M, runway into 2025","bullets":["New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.","Cash $89.4M as of June 30, 2023; net cash used in operations $7.1M in Q2; runway into 2025.","Expanded Pfizer relationship: Pfizer Ignite to handle clinical execution of CRDF-004 Phase 2 trial.","Operating expenses $12.3M for Q2 2023, up from $10.5M in Q2 2022 due to higher headcount and stock-based compensation.","Upcoming milestones: mPDAC data Q3'23, SCLC data Q3'23, TNBC data Q4'23/Q1'24."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028563","json":"https://secwatch.observer/filing/0001628280-23-028563.json","markdown":"https://secwatch.observer/filing/0001628280-23-028563.md","text":"https://secwatch.observer/filing/0001628280-23-028563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/crdf-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:31:33.468642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d06649f5e62011c5da3be35687736e3d0dec8e06","claim":"Cardiff Oncology, Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4f6af34b5ba1064287ae15574e447a86fb5a3850","claim":"Cardiff Oncology, Inc.: Filed Certificate of Elimination to remove designations of Series B, C, D, and E Convertible Preferred Stock, returning those shares to authorized but unissued preferred stock (effective 2023-08-08).","evidence_excerpt":"On August 8, 2023, Cardiff Oncology, Inc. (the “Company”) filed, with the Secretary of State of the State of Delaware, a Certificate of Elimination (the “Certificate of Elimination”) of Series B, Series C, Series D and Series E Convertible Preferred Stock removing the designation and other references to its Series B, Series C, Series D and Series E Convertible Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023028563/0001628280-23-028563-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}